Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: Minocycline

David C Hess, Susan C. Fagan

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

There is only 1 US Food and Drug Administration-approved drug for acute ischemic stroke: tissue plasminogen activator (tPA). Due to a short time window and fear of intracerebral hemorrhage (ICH), tPA remains underutilized. There is great interest in developing combination drugs to use with tPA to improve the odds of a favorable recovery and to reduce the risk of ICH. Minocycline is a broad-spectrum antibiotic that has been found to be a neuroprotective agent in preclinical ischemic stroke models. Minocycline inhibits matrix metalloproteinase-9, a biomarker for ICH associated with tPA use. Minocycline is also an anti-inflammatory agent and inhibits poly (ADP-ribose) polymerase-1. Minocycline has been safe and well tolerated in the clinical trials conducted to date.

Original languageEnglish (US)
JournalReviews in Neurological Diseases
Volume7
Issue numberSUPPL. 1
DOIs
StatePublished - Aug 20 2010

Fingerprint

Drug Repositioning
Minocycline
Tissue Plasminogen Activator
Cerebral Hemorrhage
Stroke
Safety
Matrix Metalloproteinase 9
Neuroprotective Agents
Drug Combinations
United States Food and Drug Administration
Fear
Anti-Inflammatory Agents
Biomarkers
Clinical Trials
Anti-Bacterial Agents
Pharmaceutical Preparations

Keywords

  • Acute ischemic stroke
  • Minocycline
  • MMP-9
  • PARP-1
  • Tissue plasminogen activator

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke : Minocycline. / Hess, David C; Fagan, Susan C.

In: Reviews in Neurological Diseases, Vol. 7, No. SUPPL. 1, 20.08.2010.

Research output: Contribution to journalReview article

@article{fce8271412c74d75ab9cd163aafd2989,
title = "Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: Minocycline",
abstract = "There is only 1 US Food and Drug Administration-approved drug for acute ischemic stroke: tissue plasminogen activator (tPA). Due to a short time window and fear of intracerebral hemorrhage (ICH), tPA remains underutilized. There is great interest in developing combination drugs to use with tPA to improve the odds of a favorable recovery and to reduce the risk of ICH. Minocycline is a broad-spectrum antibiotic that has been found to be a neuroprotective agent in preclinical ischemic stroke models. Minocycline inhibits matrix metalloproteinase-9, a biomarker for ICH associated with tPA use. Minocycline is also an anti-inflammatory agent and inhibits poly (ADP-ribose) polymerase-1. Minocycline has been safe and well tolerated in the clinical trials conducted to date.",
keywords = "Acute ischemic stroke, Minocycline, MMP-9, PARP-1, Tissue plasminogen activator",
author = "Hess, {David C} and Fagan, {Susan C.}",
year = "2010",
month = "8",
day = "20",
doi = "10.3909/rind7S1S0002",
language = "English (US)",
volume = "7",
journal = "Reviews in Neurological Diseases",
issn = "1545-2913",
publisher = "MedReviews LLC",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke

T2 - Minocycline

AU - Hess, David C

AU - Fagan, Susan C.

PY - 2010/8/20

Y1 - 2010/8/20

N2 - There is only 1 US Food and Drug Administration-approved drug for acute ischemic stroke: tissue plasminogen activator (tPA). Due to a short time window and fear of intracerebral hemorrhage (ICH), tPA remains underutilized. There is great interest in developing combination drugs to use with tPA to improve the odds of a favorable recovery and to reduce the risk of ICH. Minocycline is a broad-spectrum antibiotic that has been found to be a neuroprotective agent in preclinical ischemic stroke models. Minocycline inhibits matrix metalloproteinase-9, a biomarker for ICH associated with tPA use. Minocycline is also an anti-inflammatory agent and inhibits poly (ADP-ribose) polymerase-1. Minocycline has been safe and well tolerated in the clinical trials conducted to date.

AB - There is only 1 US Food and Drug Administration-approved drug for acute ischemic stroke: tissue plasminogen activator (tPA). Due to a short time window and fear of intracerebral hemorrhage (ICH), tPA remains underutilized. There is great interest in developing combination drugs to use with tPA to improve the odds of a favorable recovery and to reduce the risk of ICH. Minocycline is a broad-spectrum antibiotic that has been found to be a neuroprotective agent in preclinical ischemic stroke models. Minocycline inhibits matrix metalloproteinase-9, a biomarker for ICH associated with tPA use. Minocycline is also an anti-inflammatory agent and inhibits poly (ADP-ribose) polymerase-1. Minocycline has been safe and well tolerated in the clinical trials conducted to date.

KW - Acute ischemic stroke

KW - Minocycline

KW - MMP-9

KW - PARP-1

KW - Tissue plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=77955599953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955599953&partnerID=8YFLogxK

U2 - 10.3909/rind7S1S0002

DO - 10.3909/rind7S1S0002

M3 - Review article

C2 - 20410869

AN - SCOPUS:77955599953

VL - 7

JO - Reviews in Neurological Diseases

JF - Reviews in Neurological Diseases

SN - 1545-2913

IS - SUPPL. 1

ER -